Noxtor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Noxtor

Quick Facts

Property Description
Active ingredient Ketotifen Fumarate
Form Oral and Ophthalmic preparations
Pharmacological class H1-Antihistamine & Mast Cell Stabilizer
Common use Management of Allergic Conditions
Origin Synthetic

The Identity of Noxtor: Definition and Composition

Noxtor is a pharmaceutical product containing the active ingredient Ketotifen Fumarate, a synthetic compound broadly classified as an anti-allergic agent. The active base molecule, Ketotifen, is formulated as the Fumarate salt, which is necessary for creating a stable and bioavailable medicine suitable for therapeutic use. Its defining feature is its dual-action mechanism, which provides a differentiating benefit over single-action treatments.

This medicine is manufactured in various dosage forms, including oral preparations (for systemic use) and ophthalmic solutions (eye drops for topical use). The oral form, for instance, has historically been used in the management of asthma prophylaxis in children. Regardless of the form, it is recognized as a single-active ingredient product.

Type and Classification: Dual Mechanism and Forms

Ketotifen Fumarate belongs to a distinctive pharmacological class defined by its two synergistic physiological actions: it functions as both an H1-antihistamine and a mast cell stabilizer. In the context of relieving allergic itching, it is noted for its rapid onset of relief. This indicates that the medicine has two primary ways of helping the body react less severely to allergens.

This comprehensive profile is achieved through immediate H1-receptor blockade and sustained histamine release inhibition. The versatility of the compound allows it to be used effectively via both systemic and topical delivery methods, making it a valuable agent for both generalized allergic conditions and localized responses, such as severe ocular itching.

General Purpose: Benefits for Allergic Conditions

The overarching general purpose of this medicine is to manage and mitigate the characteristic, uncomfortable symptoms of allergic conditions, such as chronic hives or seasonal conjunctivitis. By stabilizing the immune cells and blocking the effects of mediators like histamine, the compound provides both a preventative (prophylactic) and symptomatic effect against allergic irritation and inflammation. This dual approach is used to control hypersensitivity reactions by focusing on the underlying cellular and chemical pathology, helping to reduce the overall severity of the allergic response.

What side effects are possible with Noxtor?

Possible Side Effects and Safety Information

The safety profile for medicines containing Ketotifen Fumarate (Noxtor) is differentiated based on the form of administration, with reactions officially classified by system-organ class and frequency as detailed in regulatory documents. Adverse effects are grouped into System-Organ Classes such as Nervous System Disorders, Eye Disorders, and Metabolism and Nutrition Disorders.

Officially Documented Reactions and Frequencies

For the systemic (oral) use, reactions commonly documented in official sources include dry mouth and weight gain. Uncommon effects are often related to the nervous system, such as sedation and dizziness. These effects are generally noted as transient and may be more likely to occur at the start of treatment.

For the topical (ophthalmic) use, officially classified Common reactions include localized effects such as eye irritation, burning, or stinging, as well as headache and rhinitis. Potential severe acute hypersensitivity reactions represent a general safety element documented across the regulatory profile.

High-Level Safety Constraints

Official prescribing information outlines specific safety considerations. The oral form requires caution due to the risk of potentiation of sedative effects when used concurrently with alcohol or other CNS depressants. Furthermore, special safety consideration is necessary for individuals with a history of epilepsy or a predisposition to convulsions, as well as those with severe hepatic impairment. These statements reflect the official regulatory understanding of the medicine’s risk profile, distinguishing between local and systemic effects and outlining required precautionary limitations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Ketotifen Fumarate describes manifestations that primarily affect the central nervous and cardiovascular systems following the ingestion of a large amount. Regulatory documents mandate that individuals seek immediate medical attention or call a poison control center immediately if an overdose is suspected.

Documented Overdose Manifestations

System Documented Signs and Symptoms
Central Nervous System Drowsiness (severe), confusion, disorientation, dizziness, hyperexcitability, and convulsions
Cardiovascular System Tachycardia (fast heart rate) and hypotension (low blood pressure)

Severe Outcomes and Required Actions

Regulators classify severe outcomes as including convulsions, profound sedation, reversible coma, and respiratory depression. The presence of these life-threatening symptoms requires urgent care and hospitalization for continuous monitoring.

Management is strictly symptomatic and supportive, as no specific antidote is known. Officially described supportive measures include considering gastric lavage and the administration of activated charcoal for recent ingestions. Cardiovascular monitoring is required due to potential cardiac effects. Hyperexcitability and convulsions are noted as characteristic features of acute overdosage in pediatric patients.

Therapeutic Uses of Noxtor

What Noxtor treats: main uses and benefits

Noxtor may be part of symptomatic management applied across domains where additional symptomatic support is needed for conditions involving episodic or fluctuating manifestations. The primary therapeutic function is considered relevant for easing symptoms related to physical discomfort caused by allergic or inflammatory states. This includes conditions such as allergic conjunctivitis. The active component may assist with supportive relief from symptoms that create noticeable physiological strain, specifically eye itching.

The medication is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed. The primary benefit contributes to improved comfort during periods of heightened symptoms, helping patients manage discomfort associated with inflammation and irritation.

“It is often used when symptoms intensify and supportive relief is needed, supporting the patient during difficult episodes by easing distress.”

This approach assists with maintaining functional stability when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Eye Itching

Eligibility and Restrictions for Use

The eligibility for Noxtor (Ketotifen Fumarate) is strictly defined by regulatory guidelines and varies significantly between the oral and ophthalmic formulations.

Contraindicated Populations

Use of the medicine is absolutely prohibited for individuals with a known hypersensitivity to the active substance or any excipient. The oral formulation has several additional contraindications, including for patients concurrently treated with oral antidiabetic agents or those with epilepsy or a history of seizures. Furthermore, the oral form is contraindicated for breastfeeding mothers, as excretion into breast milk is assumed. The ophthalmic formulation must not be used to treat irritation caused by wearing soft contact lenses.

Age and Life Stage Rules

  • The ophthalmic formulation is approved for adults and children 3 years of age and older, with safety and efficacy not established below this threshold.
  • The oral formulation has established use for children 6 months and older, though dose adjustment is required for infants.
  • For pregnancy, use is generally not recommended unless the benefit to the mother justifies the potential risk to the fetus, as human safety data is limited. The ophthalmic form may be used while breastfeeding, unlike the oral form.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Noxtor (Ketotifen Fumarate) is primarily defined by documented pharmacodynamic potentiation and specific co-administration restrictions, as outlined in regulatory labeling.


Drug–Drug and Substance Interactions

Co-administration with Central Nervous System (CNS) depressants, including sedatives, hypnotics, and other antihistamines, may result in the potentiation of effects, consistent with the additive action of the medicine. The use of the oral form may similarly potentiate the effects of alcohol.

A significant restriction applies to oral antidiabetic agents: this combination should be avoided due to a documented, rare risk of a reversible fall in the thrombocyte count.


Procedural and Condition-Specific Cautions

For the ophthalmic formulation, strict timing rules are mandated for co-administration. If used alongside other eye medications, a minimum 5-minute interval must be observed between the two products. Furthermore, if soft contact lenses are reinserted, a waiting period of at least 15 minutes is required after instillation.

Regulatory cautions also note potential interactions dependent on patient condition. For the oral form, the medicine may lower the seizure threshold in individuals with a history of epilepsy. Patients with severe hepatic impairment face a risk of accumulation of the unchanged drug due to potentially reduced clearance.

Mechanism of Action

Targeted Receptor and Enzyme System Modulation

Noxtor operates by selectively engaging defined biological targets, primarily acting as a modulator within specific receptor or enzyme systems. This mechanism initiates or suppresses key signaling events and influences activity in associated regulatory systems to influence the overall activity of the cellular environment.

Interruption of Signal Transduction Cascades

Once activated, the mechanism extends to modify early molecular steps within well-characterized signaling cascades. This activity occurs in contexts involving heightened pathway activation, which results in the modulation of dysregulated mediators and suppresses the excessive amplification of signaling events within the cellular environment.

Mechanistic Influence on Physiological Responses

By influencing these targeted pathways, Noxtor influences the regulation of both overactive and underactive physiological responses. Its overall mechanistic domain acts to moderate activity in overactive physiological processes. This action results in specific physiological adjustments within the targeted pathways.

Dosage and Administration Information

How to Use Noxtor: Official Administration Guidelines

Noxtor (Ketotifen Fumarate) is characterized by its dual administration routes, being available as both an oral preparation for systemic use and a topical ophthalmic solution (eye drops). The specific pattern of use is defined by the official instructions for each formulation.


Administration Protocol

Both the oral and ophthalmic forms follow a twice-daily (BID) frequency pattern, ensuring doses are administered approximately 8 to 12 hours apart. The oral dose should generally be taken with food in adults and children over three years of age.

Administration Type Standard Adult Dose Frequency Special Condition
Ophthalmic Solution One drop in the affected eye(s) Twice Daily Soft contact lenses must be removed before use
Oral Preparation 1 mg (tablet or solution) Twice Daily Must be taken with food

Population-Specific Dosing

The standard 1 mg twice-daily dose is used for both adults and pediatric patients three years of age and older. However, for younger children aged two to three years, the oral solution is administered based on body weight at a dose of 0.05 mg/ kg twice daily. Dosage adjustments are typically not required for older adults (65 years and above).


Contextual Use and Duration

The ophthalmic solution is strictly for topical use in the eye; procedural hygiene requires that the dropper tip must not be contaminated by touching the eye or any surface. For the oral preparation, continuous use for a period of two to three months may be necessary to achieve the intended prophylactic effect. If discontinuing a patient's existing prophylactic therapy, the oral preparation must be continued concurrently for a minimum of two weeks to ensure an overlap period.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Intervention Context

Studies examined a study agent designed to influence the intestinal absorption of dietary fat. Researchers explored the use of the study agent alongside interventions intended to achieve a caloric deficit. Studies examined the study agent's use in combination with a reduced-calorie diet as an intervention in body weight management.


Primary Efficacy Studies (Weight Measurement)

A series of randomized controlled trials (RCTs) evaluated the outcomes associated with the administration of this study agent, often over a one- to two-year period. Research focused on its application as part of a regimen to manage body weight.

  • Study Design: The typical study design involved participants who were overweight or obese. Participants were randomly assigned to receive either the study agent or a placebo. All participants were simultaneously enrolled in lifestyle intervention programs focusing on diet and exercise.
  • Key Findings: Studies frequently reported that the study reported a higher measured mean percentage change in body weight in the administration group compared to the placebo group. Differences in average total body weight change were often reported in the range of 2.5 kg to 4.5 kg over 12 months, depending on the trial population.
  • Administration Protocol: The clinical trial protocols included a specified administration schedule and dosage.

Cardiovascular and Metabolic Measurement

Some studies explored whether the study agent, when used in conjunction with lifestyle interventions, was associated with changes in the incidence of type 2 diabetes among obese participants.

  • Diabetes Incidence: Findings suggested a lower cumulative incidence of type 2 diabetes over four years in the treatment group compared to the placebo group. The absolute change in risk reported varied between 1.5% and 3.0% across trials.
  • Cardiovascular Markers: Research compared the measured changes associated with the study agent combined with lifestyle changes versus lifestyle changes alone on various long-term cardiovascular markers, including blood pressure and lipid profiles. While some markers showed beneficial trends in the treatment group, the studies did not establish a direct causal impact on overall cardiovascular disease events.

Safety Monitoring in Trials

Adverse events were commonly reported, primarily relating to the gastrointestinal (GI) tract.

  • Adverse Events: Adverse events were commonly reported, primarily relating to the gastrointestinal (GI) tract.
  • Inclusion Criteria: Studies have included participants who also had mild hypertension.
  • Nutrient Monitoring: Research noted that the study agent's effects on nutrient processing required a protocol that included monitoring and supplementation of fat-soluble vitamins (A, D, E, K). Severe adverse events were reported in clinical trials, and protocols often included discontinuing the study agent if such events occurred.

Key Studies & References

  1. Overweight and obesity management (NICE Guideline NG246) - Prescribing Orlistat
  2. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension

Frequently Asked Questions (FAQ)

Common questions about Noxtor (FAQ)


Q: Are there different brand names for the active ingredient in Noxtor?

Yes, the active ingredient in Noxtor is Ketotifen Fumarate. This same active substance is sold under various other brand names, particularly in its ophthalmic (eye drop) formulation, such as Alaway and Zaditor.


Q: How quickly can a person expect Noxtor to start working?

Official information for the ophthalmic solution describes a rapid onset of action, meaning an effect may be seen as early as within minutes after being applied to the eye. For the oral form, the desired preventative effect may require continuous administration over several weeks.


Q: How long does the effect of one dose of Noxtor usually last?

Regulatory labeling for the ophthalmic solution indicates that one dose is intended to provide relief for up to 12 hours. The oral form is also typically administered twice daily to maintain a consistent effect throughout the day.


Q: Can Noxtor cause issues with sleep?

The oral formulation of Noxtor lists potential side effects like temporary sedation and dizziness. Since these effects can impact the central nervous system, they may potentially affect a person's normal sleep-wake cycle.


Q: Is Noxtor safe to take if I have kidney problems?

Based on regulatory data summaries for the ophthalmic formulation, dosage adjustment is typically not required for patients with mild to moderate renal (kidney) impairment. Information specific to a person’s condition is typically reviewed by a healthcare provider.


Q: Can people with liver conditions use Noxtor?

Regulatory cautions indicate that people with severe hepatic (liver) impairment may be at a higher risk. This is due to the potential for the unchanged drug to accumulate in the body when clearance is reduced.


Q: Can Noxtor affect my ability to drive or operate machinery?

Official product information for both the oral and ophthalmic forms includes warnings about driving and using machines. This is because the medicine may cause temporary drowsiness, dizziness, or blurred vision, which could affect concentration and coordination.


Q: Is Noxtor the kind of medicine you take indefinitely or short-term?

The ophthalmic solution is officially instructed for the temporary relief of itching, suggesting shorter-term use until symptoms resolve. In contrast, the oral form is often directed to be taken continuously for a specified duration to achieve its full prophylactic (preventative) effect.


Q: Why does the official patient information mention a risk of [Specific Rare Side Effect]?

Regulatory documents and patient information are required to include all adverse events reported during clinical trials and post-marketing surveillance. This ensures that prescribers and patients are fully informed of all established risks, even those that are rare or serious in nature.


Q: Can Noxtor be crushed or mixed with food?

Official instructions for the oral preparation state it should be taken with food. However, regulatory documents do not consistently provide specific instructions about physically altering the tablet form. Physical alteration of the medication is a medical matter usually determined by a healthcare provider.


Q: Is Noxtor considered a new drug or has it been around for a while?

The active ingredient, Ketotifen Fumarate, has been studied and used globally for many years. Although the active substance is well-established, specific formulations, like the ophthalmic solution in the US, received their initial FDA approval in the early 2000s.


Q: Is Noxtor considered a controlled substance?

Official regulatory records, such as those maintained by the FDA’s DailyMed database, classify the active ingredient in Noxtor as having a DEA Schedule of None. This indicates that it is not regulated as a controlled substance.


Q: Is there a risk of becoming dependent on Noxtor?

Ketotifen Fumarate does not belong to the classes of medicines typically associated with dependence or addiction. Regulatory information does not list dependence or addiction as a known or expected risk for this medication.


Q: Does Noxtor require any special laboratory monitoring?

General lab monitoring is not typically required. However, regulatory information notes that if the oral form is combined with certain oral antidiabetic agents, monitoring of blood parameters, specifically the thrombocyte count, may be necessary due to a rare reported risk.


Q: Is the medication designed to be taken at a specific time of day?

The official administration frequency for both forms is twice daily (BID). While the dose interval must be respected (typically 8 to 12 hours apart), regulatory documents generally do not specify a required time of day, such as only morning and evening.


Q: What should I do if I feel like Noxtor isn't helping me?

Official patient instructions describe conditions, such as symptoms worsening or lasting longer than 72 hours (for the ophthalmic form), where the medicine should be discontinued and professional review sought. If the expected preventative effect of the oral form is not achieved, reviewing the condition with a healthcare professional is the standard practice.


Q: Is the active ingredient in Noxtor available as a generic medicine?

Yes, the active ingredient, Ketotifen Fumarate, is widely available under multiple generic ophthalmic products. These generic products have been approved through regulatory pathways that demonstrate bioequivalence to the original formulation.


Q: Why is the medication administered in two different ways (oral and eye drops)?

The active ingredient is a versatile compound with a dual mechanism—it acts as both an antihistamine and a mast cell stabilizer. This allows it to be effective when used locally (topical) for eye symptoms or systemically (oral) for broader allergic or preventative conditions.

How should Noxtor be stored and disposed of?

How to Store and Dispose of Noxtor (Ketotifen Fumarate Ophthalmic Solution)

Official regulatory labeling dictates strict conditions for storing and disposing of Noxtor to ensure product stability and safety.


Storage Requirements

Noxtor ophthalmic solution must be stored at controlled room temperature, specifically between 15 C and 25 C (59 F and 77 F). It is mandatory to not freeze the solution. The medicine must be kept in its original container and the bottle should be kept tightly closed when not in use. For safety, the product must be stored out of the sight and reach of children.


Disposal Instructions

Unused or expired Noxtor should not be disposed of by pouring it into a drain or flushing it down the toilet. The preferred method for disposal is through an official medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Noxtor found in:

A-Z Index: